Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 111 results for bladder cancer

  1. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

    Clinical guideline
    Last updated
    3 June 2015
    View recommendations

    Sections for CG97

  2. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

    NICE guideline
    Last updated
    1 May 2025

    Sections for NG12

  3. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  4. Urinary incontinence and pelvic organ prolapse in women: management (NG123)

    This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.

    NICE guideline
    Last updated
    24 June 2019
    View recommendations

    Sections for NG123

  5. URO17 for testing suspected bladder cancer

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  6. Urinary tract infections in adults (QS90)

    This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    15 February 2023
    View quality statements

    Sections for QS90

  7. What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer?

    satisfaction for bladder cancer? Any explanatory notes(if applicable) The urological cancers grouping (which includes...

    Research recommendation
    Published
    9 June 2015

  8. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA817

  9. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  10. Is primary radical cystectomy more effective than primary intravesical BCG (Bacille Calmette-Guérin) in high risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes?

    Calmette-Guérin) in high risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes?...

    Research recommendation
    Published
    9 June 2015

  11. Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancer

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. In patients with muscle-invasive bladder cancer suitable for radical treatment, does the use of biomarkers enable patients to select more effective treatment, and improve their outcomes, compared with treatment selected without biomarkers?

    Recommendation ID NG2/4 Question In patients with muscle-invasive bladder cancer suitable for radical treatment, does the use of...

    Research recommendation
    Published
    9 June 2015

  13. Further research on electrically stimulated intravesical chemotherapy for nonmuscle-invasive bladder cancer should include randomised controlled trials compared withstandard care, which should report details of patient selection.

    electrically stimulated intravesical chemotherapy for nonmuscle-invasive bladder cancer should include randomised controlled trials...

    Research recommendation
    Published
    18 February 2019

  14. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]

    Awaiting development Reference number: GID-TA11469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns. However, current evidence on its efficacy is limited in quality and quantity. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns....

    Research recommendation
    Published
    15 November 2019